This trial is active, not recruiting.

Conditions fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome, depression
Sponsor National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Start date September 1999
Trial size 560 participants
Trial identifier NCT00071162, NIAMS-100


The Fibromyalgia Family Study identifies and collects blood samples from families with two or more members affected with Fibromyalgia Syndrome (FMS). The primary goal of the study is to identify genes that predispose people to FMS and/or symptoms related to FMS; identifying these genes may lead to a better understanding of the disease and more effective treatments.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model family-based
Time perspective retrospective

Eligibility Criteria

Male or female participants at least 12 years old.

Inclusion Criteria - Diagnosed with fibromyalgia according to the criteria of the American College of Rheumatology - Have at least one living family member who has also been diagnosed with fibromyalgia - No other major rheumatological disease

Additional Information

Official title Fibromyalgia Family Study Registry
Description FMS predominantly affects women and is characterized by chronic widespread musculoskeletal pain, fatigue, sleep disturbance, and multiple tender points on physical examination. The pathophysiological mechanisms underlying FMS are not clearly understood, but neuroendocrine factors seem to be of major importance. Studies of familial association suggest that genetic factors play a role in FMS. This study will establish patterns of genetic linkage in families with FMS. Participating family members will undergo a brief physical exam (including tender point exam), donate a blood sample, and complete a detailed questionnaire that includes experience with pain, fatigue, depression, bowel symptoms, headache, anxiety, and physical limitations. Measurements of serum serotonin and related compounds will also be obtained. To detect genetic factors, a genome-wide linkage scan using 405 microsatellite markers will be performed.
Trial information was received from ClinicalTrials.gov and was last updated in March 2009.
Information provided to ClinicalTrials.gov by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).